The EMPOWER-Cervical-1 phase III study compared cemiplimab versus physicians choice chemotherapy (pemetrexed, irinotecan, topotecan, gemcitabine, vinorelbine) in patients with advanced cervical cancer after ≥1 lines of treatment who have progressed within 6 months of platinum therapy, regardless of PD-L1 status. The gene discussed is CD274; the disease is cervical carcinoma.